-+ 0.00%
-+ 0.00%
-+ 0.00%

CEREVANCE ANNOUNCES POSITIVE PHASE 3 ARISE RESULTS: ONCE-DAILY ORAL SOLENGEPRAS MEETS PRIMARY ENDPOINT AND DEMONSTRATES MOTOR AND NON-MOTOR BENEFITS IN PARKINSON'S DISEASE

Reuters·10/07/2026 12:02:25